Delivery of Adipose Derived Stem Cells for Healing Surgical Hernia Repairs

递送脂肪干细胞用于治愈疝气修复手术

基本信息

  • 批准号:
    8198653
  • 负责人:
  • 金额:
    $ 7.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-10 至 2011-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Over 700,000 surgical hernia repairs are performed each year in the United States and despite recent advances, a significant rate of recurrence persists. Incisional or visceral hernia repairs account for 100,000 of these surgeries costing 1.7B annually, and have a recurrence rate of 25% for an initial repair and 44% after a second repair. The incorporation of biocompatible mesh to strengthen the abdominal fascia has largely replaced high-tension suturing techniques in surgical hernia repair. Currently, the preferred biomaterials include durable synthetic mesh, which bears all the pitfalls of a permanent foreign body; absorbable mesh which does not provide enough long-term support; or bioprosthetics, which are bioabsorbable but fail at an unacceptably high rate causing recurrent hernias. Surgeons are therefore left to choose between a foreign body and a weak repair. Our goal is to accelerate healing rates after hernia repair by using bioprosthetics containing adipose-derived stem cells (ASCs). ASCs were identified in 2001, and have been used for cell therapy in many indications including bone fractures, myocardial repair and soft tissue repair. Their prohealing function is largely mediated through paracrine factors secreted at the site of injury to promote vascularization, and tissue remodeling. The product prototype we envision will be a point-of-care ASC seeded bioprosthetic that will promote faster healing times, prevent infection, and leave a biologic repair. Our bioprosthetic is designed to prevent recurrence of incisional hernias, thereby reducing inpatient follow-up care, additional surgeries, and patient distress. PUBLIC HEALTH RELEVANCE: Improving the rate of healing after surgical hernia repair will reduce pain, discomfort and follow-up care. The introduction of biologics into soft tissue healing represents a potential improvement for surgical procedures, but due to a lack of clinically viable delivery mechanisms, these strategies remain under utilized. This proposal will develop a novel bioprosthetic for the local retention of cells to improve healing rates and reduce recurrence of incisional hernia repairs. Because hernia repair is one of the most common surgical procedures world-wide, with more than 700,000 surgeries in the United States, this product will provide substantially improved clinical outcomes for a large number of patients.
描述(由申请人提供):美国每年进行超过700,000例疝修补手术,尽管最近取得了进展,但复发率仍然很高。切口或内脏疝修补术占这些手术的10万例,每年花费17亿美元,初次修补的复发率为25%,第二次修补后为44%。结合生物相容性补片以加强腹部筋膜已在很大程度上取代了外科疝修补术中的高张力疝修补技术。目前,优选的生物材料包括耐用的合成网片,其具有永久性异物的所有缺陷;不能提供足够长期支撑的可吸收网片;或生物假体,其是生物可吸收的,但以不可接受的高速率失效,导致复发性疝。因此,外科医生只能在异物和弱修复之间做出选择。我们的目标是通过使用含有脂肪源性干细胞(ASC)的生物假体来加快疝修补术后的愈合速度。ASC于2001年被鉴定,并已用于许多适应症的细胞治疗,包括骨折,心肌修复和软组织修复。它们的促愈合功能主要是通过在损伤部位分泌的旁分泌因子介导的,以促进血管形成和组织重塑。我们设想的产品原型将是一种即时护理的ASC种子生物假体,它将促进更快的愈合时间,预防感染,并留下生物修复。我们的生物假体旨在防止切口疝复发,从而减少住院随访护理,额外手术和患者痛苦。 公共卫生相关性:提高手术疝修补术后的愈合率将减少疼痛、不适和后续护理。将生物制剂引入软组织愈合代表了外科手术的潜在改进,但由于缺乏临床可行的输送机制,这些策略仍未得到充分利用。该提案将开发一种新型生物假体,用于局部保留细胞,以提高愈合率并减少切口疝修补术的复发。由于疝修补术是全球最常见的外科手术之一,在美国有超过70万例手术,因此该产品将为大量患者提供显著改善的临床结局。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bruce Lamb其他文献

Bruce Lamb的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bruce Lamb', 18)}}的其他基金

High-viability cryopreservation media for primary hepatocytes
原代肝细胞高活力冻存培养基
  • 批准号:
    8711826
  • 财政年份:
    2014
  • 资助金额:
    $ 7.31万
  • 项目类别:
Peptide-mediated attachment of non-plateable hepatocytes to surfaces
肽介导的不可电镀肝细胞与表面的附着
  • 批准号:
    8780418
  • 财政年份:
    2014
  • 资助金额:
    $ 7.31万
  • 项目类别:
Peptide-coated skin substitutes for the treatment of burn injuries and wounds
用于治疗烧伤和伤口的肽涂层皮肤替代品
  • 批准号:
    8780360
  • 财政年份:
    2012
  • 资助金额:
    $ 7.31万
  • 项目类别:
Peptide-coated skin substitutes for the treatment of burn injuries and wounds
用于治疗烧伤和伤口的肽涂层皮肤替代品
  • 批准号:
    8312066
  • 财政年份:
    2012
  • 资助金额:
    $ 7.31万
  • 项目类别:
Delivery of Adipose Derived Stem Cells for Healing Surgical Hernia Repairs
递送脂肪干细胞用于治愈疝气修复手术
  • 批准号:
    8392845
  • 财政年份:
    2011
  • 资助金额:
    $ 7.31万
  • 项目类别:
Delivery of Adipose Derived Stem Cells for Healing Surgical Hernia Repairs
递送脂肪干细胞用于治愈疝气修复手术
  • 批准号:
    8536868
  • 财政年份:
    2011
  • 资助金额:
    $ 7.31万
  • 项目类别:
Delivery of Adipose Derived Stem Cells for Healing Surgical Hernia Repairs
递送脂肪干细胞用于治愈疝气修复手术
  • 批准号:
    8484968
  • 财政年份:
    2011
  • 资助金额:
    $ 7.31万
  • 项目类别:
Recombinant expression of a biomaterial-targeting BMP-2 containing a peptide tag
含有肽标签的生物材料靶向 BMP-2 的重组表达
  • 批准号:
    7990589
  • 财政年份:
    2010
  • 资助金额:
    $ 7.31万
  • 项目类别:
Localized Growth Factor Therapy for Surgical Hernia Repair
用于疝气修复手术的局部生长因子疗法
  • 批准号:
    7998296
  • 财政年份:
    2008
  • 资助金额:
    $ 7.31万
  • 项目类别:
Localized Growth Factor Therapy for Surgical Hernia Repair
用于疝气修复手术的局部生长因子疗法
  • 批准号:
    8499488
  • 财政年份:
    2008
  • 资助金额:
    $ 7.31万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Standard Grant
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 7.31万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了